<DOC>
	<DOC>NCT00095030</DOC>
	<brief_summary>The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening HbA1c &gt;or = 7% and &lt; or = 10% Fasting cpeptide &gt; or = 1.0 umol Body Mass Index &lt; or = 41 kg/m2 Mean serum triglycerides &lt; or = 600 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Diabetes</keyword>
</DOC>